

Maryam Hassanzad¹, Ali Valinejadi², Sepideh Darougar³, Seyed Karen Hashemitari⁴, Ali Akbar Velayati⁵

¹Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran

³Department of Pediatrics, Tehran Medical Branch, Islamic Azad University of Medical Sciences, Tehran, Iran

⁴Tehran University of Medical Sciences, Tehran, Iran

⁵Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Disseminated Bacille Calmette-Guérin infection at a glance: a mini review of the literature

Abstract

Introduction: Immunodeficient children are at a high risk of disseminated *Bacillus Calmette-Guérin* [BCG] infection. We assessed the literature on clinical manifestations of BCGosis in children with specific primary immunodeficiencies.

Material and methods: We conducted a systematic review of clinical practice articles by searching Medline, PubMed, Embase, Scopus, Web of Science and Google Scholar from their inception to date.

Results: Thirty-seven articles were included regarding BCG vaccination and its dissemination in children with primary immunodeficiencies. Articles on dissemination after intravesicular BCG were excluded from the study.

Conclusions: Since disseminated BCG vaccination may be the first manifestation of a primary immunodeficiency disease, a comprehensive search for immunological defects in children developing these problems after BCG vaccination seems rational.

Key words: BCG, immunization, disseminated BCG infection, BCGosis, BCGitis

Adv Respir Med. 2019; 87: 239–242

Introduction

Considering that tuberculosis affects about one-third of the world's population and is the leading infectious cause of death in the world, immunization with *Bacille Calmette-Guérin* (BCG) is recommended to protect children against tuberculosis [1]. BCG immunization with a live attenuated bacterial vaccine derived from *Mycobacterium bovis* was first used in 1921 [2, 3] as the primary prophylaxis against tuberculosis. It is the most widely administered vaccine in the world [4]. BCG immunization during the neonatal period protects at least until 5 years of age from the most severe consequences of tuberculosis (TB) [5], such as miliary tuberculosis and tuberculosis meningitis [6], and therefore, the World Health Organization (WHO) recommends vaccination in

high burden countries [2]. Although safe, BCG vaccination may be associated with several complications, ranging from a regional disease called BCGitis to a disseminated disease, namely BCGosis [7, 8]. Adverse reactions are rare (up to 23.8% of cases) [9], with the most frequent one — purulent regional lymphadenitis — presenting as local swelling and erythema [4], followed by bone infection as the second most frequent complication [9]. Vaccination technique, dose and preparation of the vaccine and the BCG strain are significant risk factors [4, 10]. It has been reported that T cell counts in healthy infants may be suppressed after BCG vaccination but these quantitative changes have not been associated with functional derangements [11, 12]. Disseminated BCG infection, a lethal event in 50 to 71% of cases, is somewhat rarer with an estimated incidence

Address for correspondence: Sepideh Darougar, Farhikhtegan Hospital, Daneshgah Boulevard, Sattari Highway, Tehran, Iran; e-mail: sepidehdarougar@yahoo.com

DOI: 10.5603/ARM.2019.0040

Received: 14.02.2019

Copyright © 2019 PTChP

ISSN 2451–4934

of 0.1 to 4.3 per one million vaccinated children [9, 13]. Immunocompromised patients are not only susceptible to mycobacterial diseases, but also to the BCG vaccine complications [8]. These individuals may experience dissemination of the bacilli due to their underlying immunological defects. Disseminated BCG infection has been reported in severe combined immunodeficiencies [SCID], chronic granulomatous disease (CGD), complete DiGeorge syndrome and mandeliana susceptibility to mycobacterial disease (MSMD) with underlying genetic defects [9].

The aim of this study is to evaluate the most frequent clinical manifestations of disseminated BCG infections in vaccinated children with unidentified primary immunodeficiencies at the time of neonatal immunization.

Material and methods

We conducted a systematic review of scientific medical literature (Medline, PubMed, Embase, Scopus, Web of Science and Google Scholar), i.e. articles published in English on the clinical manifestations of disseminated BCG infection, with no time limitation — from the inception of the databases to date. BCG complications, BCGitis, BCGosis, and disseminated BCG infection were searched through the literature. We used free texts and their related articles to search PubMed, ISI Web of Science and EMBASE. More than 50 published articles from all over the world, including original articles, review articles and case reports were used. All the articles on disseminated BCG infection following intravesicular BCG were excluded from the study.

Discussion

The aim of the article is to review the associated signs of disseminated BCG infection in addition to the clinical manifestations of the specific underlying immunodeficiency disorder. BCG vaccination may be associated with variable local and systemic complications. Disseminated BCG infection, although rare, is a devastating complication of inadvertent BCG immunization in immunocompromised children. The most common immunodeficiencies connected with the dissemination of BCG following immunization include SCID, MSMD, CGD, DiGeorge, common variable immunodeficiency (CVID), NF-kappa B essential modulator (NEMO), tyrosine kinase 2 (TYK2) and human immunodeficiency virus [14] infection. Surprisingly, BCG dissemination

has also been reported as a rare event in a case of CVID [15, 16]. Previous studies comparing disseminated BCG infection in SCID and CGD reported that many CGD patients are more prone to cure with the anti-TB regimen in contrast to the SCID patients [8, 17–19]. CGD patients are more likely to present with lymphadenitis [8, 20]. MSMD is a clinical phenotype, extending beyond mycobacterial diseases which should be considered in all patients presenting with nontuberculous mycobacterial infections such as *Mycobacterium bovis* [21]. The subjects who develop mycobacterial disease caused by BCG, environmental mycobacteria (EM) and *M. tuberculosis* are typically resistant to other infections except salmonella [22]. By contrast, patients with CGD are less susceptible to EM [22]. The median age of onset of BCGosis reported by Ying *et al.* and Al-Hojaj *et al.* in their studies were 3.6–4 months [23, 24]. BCG-induced disease phenotypes were designated in 2006 by Hesselning *et al.* as a local, regional, distant or disseminated pattern with the two first conditions known as BCGitis and the latter two identified as BCGosis [25]. Definitive disseminated BCG infection is diagnosed basing on the existence of systemic symptoms such as fever, malaise, fatigue, weight loss or stunted growth and two or more areas of involvement beyond the BCG vaccination site, in addition to identification of *Mycobacterium bovis* BCG strain by culture and/or standard polymerase chain reaction (PCR), as well as histopathologic changes with granulomatous inflammation. Areas of involvement may include skin papules, nodules, or ulcers; lymphadenitis; lung infection; liver or spleen enlargement; osteomyelitis; mechanical obstructions of the respiratory or gastrointestinal tracts; malabsorption of nutrients and diarrhea [21]. Finding similar clinical manifestations as mentioned above through identification of *Mycobacterium tuberculosis* complex by PCR, without differentiation of *Mycobacterium bovis* BCG substrain or other members of the *Mycobacterium tuberculosis* complex and negative mycobacterial cultures, with the presence of typical histopathologic changes with granulomatous inflammation is indicative of probable disseminated BCG infection [13]. Historically, this is a disease of infants and young children [26]. Casanova in 1995 reviewed 121 published case reports of disseminated BCG infections and found 61 cases of definitive immunodeficiency among them [27]. Initial presentation includes usually local erythema preceding progressively enlarging swelling at axillary region ipsilateral to the

injection site, accompanying pus discharge. Intermittent fever, generalized lymphadenopathies, hepatosplenomegaly, cough, bone involvement, weight loss and skin rash may develop later in the course of the disease [15, 26]. Refractory cough due to recurrent lower respiratory infections is another presentation of the disease reported in several cases [28], without significant changes in chest radiography [4]. Osseous involvement is another finding in disseminated BCG infection [6]. Hemophagocytic lymphocytic histiocytosis (HLH) is a rare complication of the disease [29].

Lymphadenopathies are the most common presenting features of the disease involving axillary, cervical, mediastinal, retroperitoneal, mesenteric and inguinal regions usually with a slow resolution after treatment [4]. In contrast to tuberculosis, which may present with inflammatory conglomerations of bowel loops with adherent omentum and adjacent lymphadenopathy, this finding is not a common feature in children with disseminated BCG infection [30].

Pulmonary involvement is usually associated with pulmonary symptoms, including chronic cough with intermittent fever. Plain radiography or CT scan of the chest may reveal pneumonic infiltration [22] and hilar/mediastinal lymphadenopathies. Pulmonary nodularity may occur due to the disseminated BCG disease.

Skeletal involvement may affect the hands, arms, legs, vertebrae and orbit. BCG osteomyelitis usually occurs in the epiphysis and metaphysis and can cross the growth plate with soft tissue swelling around the affected bone [31].

Hepatic and splenic lesions with variable sizes most commonly presenting as numerous small nodules detected by imaging modalities, including ultrasound evaluation or CT scan have been reported in patients with disseminated BCG infection [4].

Disseminated BCG infection is extremely difficult to treat as there is a low chance of complete eradication of the microorganism [32].

A key point in treating disseminated BCG infections is to identify the culprit organism as soon as possible to start appropriate antibiotics [33]. However, in the patients with compatible clinical signs and symptoms, suspected of primary immunodeficiencies, a positive acid-fast bacilli smear is sufficient for anti-TB treatment to be initiated promptly, with no delay to obtain the PCR results or cultures [34].

While there are no clear guidelines on the best mode of treatment for disseminated BCG infection, aggressive therapy involving at least four

anti-TB drugs [including isoniazid, rifampicin and ethambutol plus an additional agent such as quinolone, aminoglycoside and clarithromycin] are usually initiated until complete recovery [32, 35, 36]. Then, the treatment is continued with a two-drug prophylactic regimen. Prolonged use of these drugs may cause organ toxicities and drug resistance [32], which necessitates treatment modification [36]. Because of the BCG resistance to pyrazinamide, there is no place for this drug in the treatment protocol of these children [37]. Low-level isoniazid resistance to Connaught strains has been reported in Denmark [36]. During the treatment period, close follow-up and observation of the patients is essential for reviewing the regimen when the culture and sensitivity results become available [36].

IFN- γ is an effective modality of treatment in addition to anti-TB drugs in treating patients with MSMD and CGD [11].

Whenever possible and available, hematopoietic stem cell transplantation (HSCT) is another treatment option for these children [37]. However, post-transplant inflammatory complications developed upon immune reconstitution may necessitate immune suppression which not only may affect immune recovery but also may increase the risk of opportunistic infections [32].

Unfortunately, disseminated BCG disease is one of the most common causes of death in patients with primary immunodeficiency diseases due to clinical and conventional diagnostic delay [34].

Conclusions

A history of parental consanguinity and serious recurrent infections or death in other family members are two important risk factors that should be considered before BCG vaccination. Practically, family history awareness of vaccine-related complications should be promoted in antenatal visits to induce further detailed evaluations and counseling in a sufficient period of time. Since disseminated BCG vaccination may be the first manifestation of a primary immunodeficiency disease which may lead to death later in the life, a comprehensive search for immunological defects in children developing these problems after BCG vaccination seems rational.

References:

1. Organization WH. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 2018.
2. Rezaei MS, Khotaei G, Mamishi S, et al. Disseminated Bacillus Calmette-Guérin infection after BCG vaccination. *J Trop*

- Pediatr. 2008; 54(6): 413–416, doi: [10.1093/tropej/fmn053](https://doi.org/10.1093/tropej/fmn053), indexed in Pubmed: [18593737](https://pubmed.ncbi.nlm.nih.gov/18593737/).
3. Eccles S, Mehta R. Disseminated BCG disease: A case report. *Respiratory Medicine CME*. 2011; 4(3): 112–113, doi: [10.1016/j.rmedc.2010.12.003](https://doi.org/10.1016/j.rmedc.2010.12.003).
 4. Nissen TN, Birk NM, Kjergaard J, et al. Adverse reactions to the Bacillus Calmette-Guérin (BCG) vaccine in new-born infants—an evaluation of the Danish strain 1331 SSI in a randomized clinical trial. *Vaccine*. 2016; 34(22): 2477–2482, doi: [10.1016/j.vaccine.2016.03.100](https://doi.org/10.1016/j.vaccine.2016.03.100), indexed in Pubmed: [27060379](https://pubmed.ncbi.nlm.nih.gov/27060379/).
 5. Swedish Council on Health Technology Assessment. Vaccines to Children: Protective Effect and Adverse Events: A Systematic Review. Stockholm: Swedish Council on Health Technology Assessment, SBU, 2009.
 6. Shrot S, Barkai G, Ben-Shlush A, et al. BCGitis and BCGosis in children with primary immunodeficiency — imaging characteristics. *Pediatr Radiol*. 2016; 46(2): 237–245, doi: [10.1007/s00247-015-3464-z](https://doi.org/10.1007/s00247-015-3464-z), indexed in Pubmed: [26454840](https://pubmed.ncbi.nlm.nih.gov/26454840/).
 7. Sadeghi-Shabestari M, Rezaei N. Disseminated bacille Calmette-Guérin in Iranian children with severe combined immunodeficiency. *Int J Infect Dis*. 2009; 13(6): e420–e423, doi: [10.1016/j.ijid.2009.02.008](https://doi.org/10.1016/j.ijid.2009.02.008), indexed in Pubmed: [19403320](https://pubmed.ncbi.nlm.nih.gov/19403320/).
 8. Norouzi S, Aghamohammadi A, Mamishi S, et al. Bacillus Calmette-Guérin (BCG) complications associated with primary immunodeficiency diseases. *J Infect*. 2012; 64(6): 543–554, doi: [10.1016/j.jinf.2012.03.012](https://doi.org/10.1016/j.jinf.2012.03.012), indexed in Pubmed: [22430715](https://pubmed.ncbi.nlm.nih.gov/22430715/).
 9. Sadeghi-Shabestari M, Ansarin K, Maljaei SH, et al. Immunologic aspects of patients with disseminated bacille Calmette-Guérin disease in north-west of Iran. *Ital J Pediatr*. 2009; 35: 42, doi: [10.1186/1824-7288-35-42](https://doi.org/10.1186/1824-7288-35-42), indexed in Pubmed: [20030825](https://pubmed.ncbi.nlm.nih.gov/20030825/).
 10. Anderson EJ, Webb EL, Mawa PA, et al. The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda. *Vaccine*. 2012; 30(12): 2083–2089, doi: [10.1016/j.vaccine.2012.01.053](https://doi.org/10.1016/j.vaccine.2012.01.053), indexed in Pubmed: [22300718](https://pubmed.ncbi.nlm.nih.gov/22300718/).
 11. Shirvani F, Chavoshzadeh Z, Arjmand R, et al. Four-month-old boy with fever, hepatosplenomegaly and diffuse pulmonary infiltrations. *Archives of Clinical Infectious Diseases*. 2012; 7(2), doi: [10.5812/archcid.13947](https://doi.org/10.5812/archcid.13947).
 12. Taştan Y, Arvas A, Demir G, et al. Influence of Bacillus Calmette-Guérin vaccination at birth and 2 months old age on the peripheral blood T-cell subpopulations [gamma/delta and alpha-beta T cell]. *Pediatr Allergy Immunol*. 2005; 16(8): 624–629, doi: [10.1111/j.1399-3038.2005.00329.x](https://doi.org/10.1111/j.1399-3038.2005.00329.x), indexed in Pubmed: [16343082](https://pubmed.ncbi.nlm.nih.gov/16343082/).
 13. Bernatowska EA, Wolska-Kusnierz B, Pac M, et al. Disseminated bacillus Calmette-Guérin infection and immunodeficiency. *Emerg Infect Dis*. 2007; 13(5): 799–801, doi: [10.3201/eid1305.060865](https://doi.org/10.3201/eid1305.060865), indexed in Pubmed: [18044052](https://pubmed.ncbi.nlm.nih.gov/18044052/).
 14. Gorde VA, Shivde S, Kashyapi B, et al. Dignostic dilemma due to severe BCGosis. *Indian Journal of Urology*. ; 2008: 24.
 15. Shahmohammadi S, Saffar MJ, Rezaei MS. BCG-osis after BCG vaccination in immunocompromised children: Case series and review. *Journal of Pediatrics Review*. 2014;2. ; 1: 62–74.
 16. Lee WI, Huang JL, Yeh KW, et al. Immune defects in active mycobacterial diseases in patients with primary immunodeficiency diseases (PIDs). *J Formos Med Assoc*. 2011; 110(12): 750–758, doi: [10.1016/j.jfma.2011.11.004](https://doi.org/10.1016/j.jfma.2011.11.004), indexed in Pubmed: [22248828](https://pubmed.ncbi.nlm.nih.gov/22248828/).
 17. Movahedi Z, Norouzi S, Mamishi S, et al. BCGiosis as a presenting feature of a child with chronic granulomatous disease. *Braz J Infect Dis*. 2011; 15(1): 83–86, indexed in Pubmed: [21412596](https://pubmed.ncbi.nlm.nih.gov/21412596/).
 18. Afshar Paiman S, Siadati A, Mamishi S, et al. Disseminated Mycobacterium bovis infection after BCG vaccination. *Iran J Allergy Asthma Immunol*. 2006; 5(3): 133–137, doi: [10.5812/ijaai.133137](https://doi.org/10.5812/ijaai.133137), indexed in Pubmed: [17237565](https://pubmed.ncbi.nlm.nih.gov/17237565/).
 19. Vieira AP, Vasconcelos J, Fernandes JC, et al. Lymphadenopathy after BCG vaccination in a child with chronic granulomatous disease. *Pediatr Dermatol*. 2004; 21(6): 646–651, doi: [10.1111/j.0736-8046.2004.21606.x](https://doi.org/10.1111/j.0736-8046.2004.21606.x), indexed in Pubmed: [15575848](https://pubmed.ncbi.nlm.nih.gov/15575848/).
 20. van den Berg JM, van Koppen E, Ahlin A, et al. Chronic granulomatous disease: the European experience. *PLoS One*. 2009; 4(4): e5234, doi: [10.1371/journal.pone.0005234](https://doi.org/10.1371/journal.pone.0005234), indexed in Pubmed: [19381301](https://pubmed.ncbi.nlm.nih.gov/19381301/).
 21. Rezaei MS, Ahangarkani F, Sadeghi R, et al. Evaluation of children with complication of bcg vaccination in north of Iran. *International Journal of Pediatrics*. 2017; 3: 4479– 4488.
 22. Bustamante J, Aksu G, Vogt G, et al. BCG-osis and tuberculosis in a child with chronic granulomatous disease. *J Allergy Clin Immunol*. 2007; 120(1): 32–38, doi: [10.1016/j.jaci.2007.04.034](https://doi.org/10.1016/j.jaci.2007.04.034), indexed in Pubmed: [17544093](https://pubmed.ncbi.nlm.nih.gov/17544093/).
 23. Ying W, Sun J, Liu D, et al. Clinical characteristics and immunogenetics of BCGosis/BCGitis in Chinese children: a 6 year follow-up study. *PLoS One*. 2014; 9(4): e94485, doi: [10.1371/journal.pone.0094485](https://doi.org/10.1371/journal.pone.0094485), indexed in Pubmed: [24722620](https://pubmed.ncbi.nlm.nih.gov/24722620/).
 24. Al-Hajoj S, Memish Z, Abuljadayel N, et al. Molecular confirmation of Bacillus Calmette-Guérin vaccine related adverse events among Saudi Arabian children. *PLoS One*. 2014; 9(11): e113472, doi: [10.1371/journal.pone.0113472](https://doi.org/10.1371/journal.pone.0113472), indexed in Pubmed: [25409184](https://pubmed.ncbi.nlm.nih.gov/25409184/).
 25. Hesseling AC, Rabie H, Marais BJ, et al. Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. *Clin Infect Dis*. 2006; 42(4): 548–558, doi: [10.1086/499953](https://doi.org/10.1086/499953), indexed in Pubmed: [16421800](https://pubmed.ncbi.nlm.nih.gov/16421800/).
 26. Poudel P, Chitlangia M. Disseminated BCG Infection (BCGosis) After BCG Vaccination. *Journal of Nepal Paediatric Society*. 2014; 34(1): 62–64, doi: [10.3126/jnps.v34i1.9679](https://doi.org/10.3126/jnps.v34i1.9679).
 27. Casanova JL, Jouanguy E, Lamhamedi S, et al. Immunological conditions of children with BCG disseminated infection. *Lancet*. 1995; 346(8974): 581, doi: [10.1016/s0140-6736\(95\)91421-8](https://doi.org/10.1016/s0140-6736(95)91421-8), indexed in Pubmed: [7658805](https://pubmed.ncbi.nlm.nih.gov/7658805/).
 28. Wahadneh A, Bin-Dahman H, Hababbeh Z, et al. Successful second bone marrow transplantation in Omenn's syndrome after bone marrow aplasia: a case report. *Pediatr Transplant*. 2012; 16(2): E43–E48, doi: [10.1111/j.1399-3046.2010.01413.x](https://doi.org/10.1111/j.1399-3046.2010.01413.x), indexed in Pubmed: [21108710](https://pubmed.ncbi.nlm.nih.gov/21108710/).
 29. Bholra N, Sarangi R, Dey P, et al. Disseminated BCG-osis with haemophagocytosis, tubercular bacteraemia, and unusual haematological findings with its haematology analyser-based expression. *Journal of Hematopathology*. 2018; 11(3): 87–92, doi: [10.1007/s12308-018-0327-1](https://doi.org/10.1007/s12308-018-0327-1).
 30. Andronikou S, Wieselthaler N. Modern imaging of tuberculosis in children: thoracic, central nervous system and abdominal tuberculosis. *Pediatr Radiol*. 2004; 34(11): 861–875, doi: [10.1007/s00247-004-1236-2](https://doi.org/10.1007/s00247-004-1236-2), indexed in Pubmed: [15372216](https://pubmed.ncbi.nlm.nih.gov/15372216/).
 31. Teo HEL, Peh WCG. Skeletal tuberculosis in children. *Pediatr Radiol*. 2004; 34(11): 853–860, doi: [10.1007/s00247-004-1223-7](https://doi.org/10.1007/s00247-004-1223-7), indexed in Pubmed: [15278319](https://pubmed.ncbi.nlm.nih.gov/15278319/).
 32. Lee PPw. Disseminated bacillus calmette-guérin and susceptibility to mycobacterial infections-implications on bacillus calmette-guérin vaccinations. *Ann Acad Med Singapore*. 2015; 44(8): 297–301, indexed in Pubmed: [26477962](https://pubmed.ncbi.nlm.nih.gov/26477962/).
 33. Wang LH, Yen CL, Chang TC, et al. Impact of molecular diagnosis on treating Mendelian susceptibility to mycobacterial diseases. *J Microbiol Immunol Infect*. 2012; 45(6): 411–417, doi: [10.1016/j.jmii.2012.08.017](https://doi.org/10.1016/j.jmii.2012.08.017), indexed in Pubmed: [23036270](https://pubmed.ncbi.nlm.nih.gov/23036270/).
 34. Hassine AB, Marzouk M, Bargui H, et al. Disseminated Bacille Calmette-Guérin Infection in Immunodeficient Infants: Report of Two Cases. *Archives of Pediatric Infectious Diseases*. 2016; 5(2), doi: [10.5812/pedinflect.37490](https://doi.org/10.5812/pedinflect.37490).
 35. Al-Mousa H. An infant with disseminated bacillus Calmette-Guérin infection (BCGitis). *International Journal of Pediatrics and Adolescent Medicine*. 2014; 1(2): 89–92, doi: [10.1016/j.ijpam.2014.11.005](https://doi.org/10.1016/j.ijpam.2014.11.005).
 36. Diagnostic criteria for BCG disseminated infections in primary immunodeficiencies. [Internet]. ESID. 2015 [cited 30 May 2015].
 37. Shirvani F, Karimi A, Rajabnejad M. BCG Vaccination as a Prevention Strategy, Threats and Benefits. *Archives of Pediatric Infectious Diseases*. 2016; 4(2), doi: [10.5812/pedinflect.30180](https://doi.org/10.5812/pedinflect.30180).